

Please
staple your
payment
here
請將股款
緊釘在此

This Application Form uses the same terms as defined in the prospectus of Shandong Boan Biotechnology Co., Ltd. (the “Company”) of December 19, 2022 (the “Prospectus”).

本申請表格使用山東博安生物技術股份有限公司(「本公司」)於2022年12月19日刊發的招股章程(「招股章程」)所界定的相同詞彙。

Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. The Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.

本申請表格及招股章程概不構成在進行要約、游說或出售發售股份即屬違法的任何司法權區要約出售或游說要約購買發售股份。倘無根據美國證券法登記或豁免登記，發售股份不得在美國提呈發售或出售。

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction.

本申請表格及招股章程概不得在任何根據當地法例不得發送、派發或複製本申請表格及招股章程的司法權區以任何方式發送或派發或複製(不論全部或部分)。

Copies of the Prospectus, all related Application Forms and the other documents specified in the “Documents Delivered to the Registrar of Companies and Documents on Display” section in Appendix VII to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), Hong Kong Securities Clearing Company Limited (“HKSCC”), the Securities and Futures Commission of Hong Kong (the “SFC”) and the Registrar of Companies in Hong Kong take no responsibility for the contents of these documents.

招股章程、所有相關申請表格及招股章程附錄七「送呈公司註冊處處長及展示文件」一節所述其他文件已根據香港法例第32章公司(清盤及雜項條文)條例第342C條規定送呈香港公司註冊處處長登記。香港交易及結算所有限公司、香港聯合交易所有限公司(「聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對此等文件的內容概不負責。

Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的股份有限公司)

Stock Code : 6955

股份代號 : 6955

Offer Price : HK\$19.80 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund)

發售價 : 每股H股19.80港元，另加1.0%經紀佣金、0.0027%證監會交易徵費、0.005%聯交所交易費及0.00015%會財局交易徵費(須於申請時以港元繳足且可予退還)

Applicants' declaration

I/We agree to the terms and conditions and application procedures in this Application Form and the Prospectus. Please refer to the “D. Effect of completing and submitting this Application Form” section of this Application Form.

申請人聲明

本人/我們同意本申請表格及招股章程的條款及條件以及申請程序。請參閱本申請表格「D.填交本申請表格的效用」一節。

Warning: Only one application may be made for the benefit of any person for Reserved Shares on a BLUE Application Form. The following are liable to be rejected: multiple or suspected multiple applications for Reserved Shares and applications where cheques or banker's cashier orders are dishonoured upon the first presentation.

警告：任何人士僅可為其利益以藍色申請表格就預留股份提出一次申請。下列情況將被拒絕受理：就預留股份提出的重複或疑屬重複申請以及支票或銀行本票在首次過戶時未能兌現的申請。

Assured Entitlement 保證配額

BLUE Form 藍表 (Assured Entitlement 保證配額)
Please use this Application Form if you are a Qualifying Luye Pharma Shareholder
閣下如為合資格綠葉製藥股東，請使用本申請表格

Name(s) and address of the Qualifying Luye Pharma Shareholder
合資格綠葉製藥股東姓名/名稱及地址

User ID 使用者編號

Access Code 通行編號

Form for Name(s) and address of the Qualifying Luye Pharma Shareholder

CCS3829

Apply for Assured Entitlement of Reserved Shares
You may apply for a number of Reserved Shares pursuant to your Assured Entitlement that is equal to or less than the number stated in Box B. If you intend to apply for a number of Reserved Shares that is less than your Assured Entitlement, you MUST apply for a number which is one of the numbers set out in the table below (other than HKSCC Nominees).

Shandong Boan Biotechnology Co., Ltd. 山东博安生物技术股份有限公司 (Stock Code 股份代號 6955)
(HK\$19.80 per Reserved Share 每股預留股份19.80港元)
NUMBER OF RESERVED SHARES THAT MAY BE APPLIED FOR AND PAYMENTS
可供申請預留股份數目及應繳款項

Table with 8 columns: No. of Reserved Shares applied for, Amount payable on application, No. of Reserved Shares applied for, Amount payable on application, No. of Reserved Shares applied for, Amount payable on application, No. of Reserved Shares applied for, Amount payable on application.

Write down the number of Reserved Shares you want to apply for and the total amount payable in the following appropriate boxes in ink (preferably in black) and mark "X" in the corresponding boxes underneath.

Number of Reserved Shares applied for and Total amount of remittance (HK\$) grids for marking 'X'.

You must pay for the Reserved Shares applied for pursuant to your Assured Entitlement by a separate cheque or banker's cashier order.
閣下必須以獨立開出的支票或銀行本票支付根據 閣下的保證配額所申請的預留股份。

Cheque/Banker's cashier order number*
Name of bank on which cheque/banker's cashier order is drawn*
Contact telephone no.

Signed by (all) applicant(s) (all joint applicants must sign):
由(所有)申請人簽署(所有聯名申請人必須簽署):

You (or, if you are joint applicants, the first-named applicant) must provide your Hong Kong identity card number/passport number/Hong Kong business registration certificate number (Please delete as appropriate)
閣下或(倘 閣下為聯名申請人) 排名首位申請人必須提供 香港身份證號碼/護照號碼/ 香港商業登記號碼(請刪除不用者)

Date 日期: / /
D M Y

Please
staple your
payment
here
請將股款
緊釘在此

This Application Form uses the same terms as defined in the prospectus of Shandong Boan Biotechnology Co., Ltd. (the “Company”) of December 19, 2022 (the “Prospectus”).

本申請表格使用山東博安生物技術股份有限公司(「本公司」)於2022年12月19日刊發的招股章程(「招股章程」)所界定的相同詞彙。

Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. The Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.

本申請表格及招股章程概不構成在進行要約、游說或出售發售股份即屬違法的任何司法權區要約出售或游說要約購買發售股份。倘無根據美國證券法登記或豁免登記，發售股份不得在美國提呈發售或出售。

This Application Form and the Prospectus may not be forwarded or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction.

本申請表格及招股章程概不得在任何根據當地法例不得發送、派發或複製本申請表格及招股章程的司法權區內以任何方式發送或派發或複製(不論全部或部分)。

Copies of the Prospectus, all related Application Forms and the other documents specified in the “Documents Delivered to the Registrar of Companies and Documents on Display” section in Appendix VII to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), Hong Kong Securities Clearing Company Limited (“HKSCC”), the Securities and Futures Commission of Hong Kong (the “SFC”) and the Registrar of Companies in Hong Kong take no responsibility for the contents of these documents.

招股章程、所有相關申請表格及招股章程附錄七「送呈公司註冊處處長及展示文件」一節所述其他文件已根據香港法例第32章公司(清盤及雜項條文)條例第342C條規定送呈香港公司註冊處處長登記。香港交易及結算所有限公司、香港聯合交易所有限公司(「聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對此等文件的內容概不負責。

Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

Stock Code : 6955

股份代號 : 6955

Offer Price : HK\$19.80 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund)

發售價 : 每股H股19.80港元，另加1.0%經紀佣金、0.0027%證監會交易徵費、0.005%聯交所交易費及0.00015%會財局交易徵費(須於申請時以港元繳足且可予退還)

Applicants' declaration

I/We agree to the terms and conditions and application procedures in this Application Form and the Prospectus. Please refer to the “D. Effect of completing and submitting this Application Form” section of this Application Form.

申請人聲明

本人/我們同意本申請表格及招股章程的條款及條件以及申請程序。請參閱本申請表格「D.填交本申請表格的效用」一節。

Warning: Only one application may be made for the benefit of any person for Reserved Shares on a BLUE Application Form. The following are liable to be rejected: multiple or suspected multiple applications for Reserved Shares and applications where cheques or banker's cashier orders are dishonoured upon the first presentation.

警告：任何人士僅可為其利益以藍色申請表格就預留股份提出一次申請。下列情況將被拒絕受理：就預留股份提出的重複或疑屬重複申請以及支票或銀行本票在首次過戶時未能兌現的申請。

BLUE Form 藍表 (Excess Application 超額申請)
Please use this Application Form if you are a Qualifying Luye Pharma Shareholder
閣下如為合資格綠葉製藥股東，請使用本申請表格

Name(s) and address of the Qualifying Luye Pharma Shareholder
合資格綠葉製藥股東姓名/名稱及地址

User ID 使用者編號

Access Code 通行編號

CCS3829

Apply for Excess Reserved Shares

Other than your Assured Entitlement, you may apply for excess Reserved Shares. If you intend to apply for excess Reserved Shares, you MUST apply for a number of excess Reserved Shares which is one of the numbers set out in the table below (other than HKSCC Nominees).

You need to complete and sign this Application Form and submit one cheque (or banker's cashier order) for the exact amount of remittance in the table below.

申請超額的預留股份

除保證配額外，閣下亦可申請超額預留股份。倘閣下擬申請超額預留股份，閣下必須申請下表中載列的其中一個超額預留股份數目(香港結算代理人除外)。

閣下須填妥及簽署本申請表格並提交一張支票(或銀行本票)支付下表中載列的確切金額。

Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 (Stock Code 股份代號 6955)
(HK\$19.80 per Reserved Share 每股預留股份19.80港元)
NUMBER OF RESERVED SHARES THAT MAY BE APPLIED FOR AND PAYMENTS
可供申請預留股份數目及應繳款項

Table with 8 columns: No. of Reserved Shares applied for, Amount payable on application (HK\$), No. of Reserved Shares applied for, Amount payable on application (HK\$), No. of Reserved Shares applied for, Amount payable on application (HK\$), No. of Reserved Shares applied for, Amount payable on application (HK\$).

Write down the number of Reserved Shares you want to apply for and the total amount payable in the following appropriate boxes in ink (preferably in black) and mark "X" in the corresponding boxes underneath.
請在以下適當空格內用墨水筆或原子筆(以黑色為佳)填寫閣下擬申請認購的預留股份數目及應繳總額，並在相應空格內加上「X」。

Number of Excess Reserved Shares applied for (申請認購的超額預留股份數目) and Total amount of remittance (HK\$) (付款總額(港元)) grid.

You must pay for the excess Reserved Shares applied for by a separate cheque or banker's cashier order.
閣下必須以獨立開出的支票或銀行本票支付所申請的超額預留股份。

- * Cheque or banker's cashier order should be crossed "Account Payee Only" and made payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED - BOAN BIOTECHNOLOGY PREFERENTIAL OFFER".
* 支票或銀行本票須以「只准入抬頭人賬戶」方式劃線開出，並須註明抬頭人為「中國銀行(香港)代理人有限公司-博安生物技術優先發售」。
* 申請人名稱/排名首位的聯名申請人名稱須與在支票/銀行本票的預印名稱或由銀行授權人士證明/在支票/銀行本票背書的名稱相同。

Cheque/Banker's cashier order number*
支票/銀行本票號碼*

Name of bank on which cheque/banker's cashier order is drawn*
支票/銀行本票的付款銀行名稱*

Contact telephone no.
聯絡電話號碼

You (or, if you are joint applicants, the first-named applicant) must provide your Hong Kong identity card number/passport number/Hong Kong business registration certificate number (Please delete as appropriate)

閣下或(倘閣下為聯名申請人)排名首位申請人必須提供香港身份證號碼/護照號碼/香港商業登記號碼(請刪除不適用者)

Signed by (all) applicant(s) (all joint applicants must sign):
由(所有)申請人簽署(所有聯名申請人必須簽署):

Signature box

Date 日期: ... D日 ... M月 ... Y年

Application Form for Assured Entitlement 保證配額申請表格

For Qualifying Luye Pharma Shareholders, applications will be accepted until
12:00 noon on Thursday, December 22, 2022.

You must read the conditions and instructions attached to this
Application Form. To be valid, you must complete all applicable parts
of this Application Form. Please write clearly in English and in ink.

合資格綠葉製藥股東的截止接受申請時間為
2022年12月22日(星期四)中午十二時正。
閣下務必細閱本申請表格隨附的條件及指示。
本申請表格各適用部分必須以英文用墨水筆或
原子筆清楚填妥，方為有效。

To: Shandong Boan Biotechnology Co., Ltd.
Joint Sponsors
Overall Coordinators
Joint Global Coordinators
Joint Bookrunners
Joint Lead Managers
Hong Kong Underwriters
Capital Market Intermediaries

致： 山东博安生物技术股份有限公司
聯席保薦人
整體協調人
聯席全球協調人
聯席賬簿管理人
聯席牽頭經辦人
香港包銷商
資本市場中介人

I/We:

- being the Qualifying Luye Pharma Shareholder(s) named overleaf, **apply** for the number of Reserved Shares specified or deemed to be specified, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association of the Company;
- **enclose** payment in full for the Reserved Shares applied for at the Offer Price of HK\$19.80 per Offer Share, plus a 1% brokerage fee, a 0.0027% SFC transaction levy, a 0.00015% AFRC transaction levy and a 0.005% Stock Exchange trading fee;
- **undertake and agree** to accept the Reserved Shares applied for, or any lesser number allotted to me/us on this application;
- **warrant** that this is the only application made by me/us for Reserved Shares for my/our Assured Entitlement for my/our own benefit;
- **understand and confirm** that these declarations and representations will be relied upon by the Company and the Overall Coordinators in deciding whether or not to make any allotment of Reserved Shares to me/us in response to this application and that I/we may be prosecuted for making a false declaration;
- **authorize** the Company to place my/our name(s) on the register of members of the Company as the holder(s) of any Reserved Shares to be allotted to me/us and such other registers as required under the Articles of Association of the Company, and despatch any share certificate(s) (where applicable) and/or any refund cheque(s) (where applicable) to me/us by ordinary post at my/our own risk to the address stated in this Application Form unless I/we have applied for 100,000 Reserved Shares or more and I/we am/are eligible to collect any share certificate(s) and/or any refund cheque (where applicable) personally, as provided in this Application Form;
- **undertake** to sign all documents and to do all things necessary to enable me/us to be registered as the holder of the Reserved Shares to be allocated to me/us, and as required by the Articles of Association of the Company;
- **request** that any refund cheque(s) be made payable to me/the first-named of us (in the case of joint applicants) in this Application Form;

本人/我們：

- 乃名列背頁之合資格綠葉製藥股東，按照招股章程及本申請表格所載條款及條件以及在 貴公司組織章程細則的規限下，申請所指定或視作指定數目的預留股份；
- 隨附以發售價每股發售股份19.80港元計算申請認購預留股份所需的全數付款，另加1%經紀佣金、0.0027%證監會交易徵費、0.00015% 會財局交易徵費及0.005%聯交所交易費；
- 承諾及同意接納本人/我們就本申請所申請認購或獲配發的任何較少數目的預留股份；
- 保證是項申請乃本人/我們就預留股份為本人/我們本身利益就本人/我們的保證配額提出的唯一申請；
- 明白及確認 貴公司及整體協調人將依賴該等聲明及陳述而決定是否因應本申請向本人/我們配發任何預留股份，本人/我們如作出虛假聲明，則可能會被檢控；
- 授權 貴公司將本人/我們的姓名/名稱列入 貴公司股東名冊，作為本人/我們將獲配發的任何預留股份的持有人，及列入 貴公司組織章程細則規定的其他名冊，並按本申請表格上所示地址以普通郵遞方式向本人/我們寄發任何股票(如適用)及/或任何退款支票(如適用)，郵誤風險概由本人/我們自行承擔，除非本人/我們申請100,000股或以上預留股份，且本人/我們符合資格按本申請表格規定親自領取任何股票及/或任何退款支票(如適用)；
- 承諾簽署所有文件並進行所有必要的事宜，以及根據 貴公司組織章程細則規定讓本人/我們登記為本人/我們獲分配的預留股份的持有人；
- 要求任何退款支票以本人/本申請表格內我們的排名首位者(倘屬聯名申請人)為抬頭人；

- **have** read the terms and conditions and application procedures set out on the pages attached to this Application Form and in the Prospectus and agree to be bound by them, and am aware of the restrictions on the Preferential Offering described in the Prospectus;
 - **represent, warrant and undertake** that the allotment of, or application for, the Reserved Shares would not require the Company, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters or the Capital Market Intermediaries to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong;
 - **represent, warrant and undertake** that I am not/we are not restricted by any applicable laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allotted or taking up any Reserved Shares; that I/we understand that the Reserved Shares have not been and will not be registered under the U.S. Securities Act; and that I/we will acquire the Reserved Shares in an “**offshore transaction**” (within the meaning of Regulation S); and
 - **agree** that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.
- 已細閱本申請表格隨附各頁及招股章程所載的條款和條件及申請程序並同意受其約束，且知悉招股章程所述有關優先發售的限制；
 - **聲明、保證及承諾**獲配發或申請認購預留股份不會引致 貴公司、聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人、聯席牽頭經辦人、包銷商或資本市場中介人須遵從香港以外任何地區的任何法律或法規的任何規定(不論是否具有法律效力)；
 - **聲明、保證及承諾**本人/我們並非香港或其他地區任何適用法律規定不得作出是項申請、支付任何申請款項或獲配發或接納任何預留股份的受限制人士；及本人/我們明白預留股份並無亦將不會根據美國證券法登記，而本人/我們將以「**離岸交易**」(定義見S規例)中購買預留股份；及
 - **同意**本申請、任何對本申請的接納以及因此訂立的合約，將受香港法例規管及按其詮釋。

Warning:

- It is important that you read the terms and conditions and application procedures overleaf.
- You must sign this application in writing (and not by way of personal chop), otherwise the application is liable to be rejected.
- Only one application may be made for the benefit of any person for Reserved Shares on a **BLUE** Application Form. The following are liable to be rejected: multiple or suspected multiple applications for Reserved Shares and applications where cheques or banker's cashier orders are dishonoured upon the first presentation.
- You may be prosecuted if you make a false declaration.
- All information stated in this Application Form must be the same as that maintained by Luye Pharma China Holdings Limited or any of its wholly-owned subsidiaries.
- **You must complete this application in English in BLOCK letters (except Chinese name) unless otherwise stated, otherwise the application is liable to be rejected.**
- Any alteration to any application detail that you provide on this Application Form should be authorized by the signature of the applicant.
- You or, if you are joint applicants, the first-named applicant must provide your Hong Kong identity card number/passport number/Hong Kong business registration certificate number.

警告：

- 閣下必須細閱背頁的條款和條件及申請程序。
- 閣下必須以書面方式(不得以個人印章方式)簽署本申請，否則申請將被拒絕受理。
- 僅可為任何人士利益以**藍色**申請表格就預留股份提出一次申請。下列情況將被拒絕受理：就預留股份提出的重複或疑屬重複申請以及支票或銀行本票在首次過戶時未能兌現的申請。
- 倘 閣下作出虛假聲明，則可遭檢控。
- 本申請表格中聲明的所有資料必須與Luye Pharma China Holdings Limited或其任何全資附屬公司所保存者相同。
- 除中文姓名/名稱外，閣下必須以英文正楷填妥本申請(除非另有指明)，否則申請將被拒絕受理。
- 閣下於本申請表格提供的任何申請資料如有任何更改，應由申請人簽署授權。
- 閣下或(倘 閣下為聯名申請人)排名首位申請人必須提供香港身份證號碼/護照號碼/香港商業登記號碼。

Application Form for Excess Reserved Shares 超額預留股份申請表格

For Qualifying Luye Pharma Shareholders, applications will be accepted until 12:00 noon on Thursday, December 22, 2022.

You must read the conditions and instructions attached to this Application Form. To be valid, you must complete all applicable parts of this Application Form. Please write clearly in English and in ink.

合資格綠葉製藥股東的截止接受申請時間為2022年12月22日(星期四)中午十二時正。閣下務必細閱本申請表格隨附的條件及指示。本申請表格各適用部分必須以英文用墨水筆或原子筆清楚填妥，方為有效。

To: Shandong Boan Biotechnology Co., Ltd.
Joint Sponsors
Overall Coordinators
Joint Global Coordinators
Joint Bookrunners
Joint Lead Managers
Hong Kong Underwriters
Capital Market Intermediaries

致： 山东博安生物技术股份有限公司
聯席保薦人
整體協調人
聯席全球協調人
聯席賬簿管理人
聯席牽頭經辦人
香港包銷商
資本市場中介人

I/We:

- being the Qualifying Luye Pharma Shareholder(s) named overleaf, **apply** for the number of excess Reserved Shares specified or deemed to be specified, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association of the Company;
- enclose** payment in full for the excess Reserved Shares applied for at the Offer Price of HK\$19.80 per Offer Share, plus a 1% brokerage fee, a 0.0027% SFC transaction levy, a 0.00015% AFRC transaction levy and a 0.005% Stock Exchange trading fee;
- undertake** and **agree** to accept the excess Reserved Shares applied for, or any lesser number allotted to me/us on this application;
- warrant** that this is the only application made by me/us for excess Reserved Shares for my/our own benefit;
- understand** and **confirm** that these declarations and representations will be relied upon by the Company, the Joint Global Coordinators and the Overall Coordinators in deciding whether or not to make any allotment of excess Reserved Shares to me/us in response to this application and that I/we may be prosecuted for making a false declaration;
- authorize** the Company to place my/our name(s) on the register of members of the Company as the holder(s) of any excess Reserved Shares to be allotted to me/us and such other registers as required under the Articles of Association of the Company, and despatch any share certificate(s) (where applicable) and/or any refund cheque(s) (where applicable) to me/us by ordinary post at my/our own risk to the address stated in this Application Form unless I/we have applied for 100,000 excess Reserved Shares or more and I/we are eligible to collect any share certificate(s) and/or any refund cheque (where applicable) personally, as provided in this Application Form;
- undertake** to sign all documents and to do all things necessary to enable me/us to be registered as the holder of the excess Reserved Shares to be allocated to me/us, and as required by the Articles of Association of the Company;
- request** that any refund cheque(s) be made payable to me/the first-named of us (in the case of joint applicants) in this Application Form;

本人/我們：

- 乃名列背頁之合資格綠葉製藥股東，按照招股章程及本申請表格所載條款及條件以及在 貴公司組織章程細則的規限下，申請所指定或視作指定數目的超額預留股份；
- 隨附以發售價每股發售股份19.80港元計算申請認購超額預留股份所需的全數付款，另加1%經紀佣金、0.0027%證監會交易徵費、0.00015%會財局交易徵費及0.005%聯交所交易費；
- 承諾**及**同意**接納本人/我們就本申請所申請認購的超額預留股份，或獲配發的任何較少數目；
- 保證**是項申請乃本人/我們就超額預留股份為本人/我們本身利益作出的唯一申請；
- 明白及確認** 貴公司、聯席全球協調人及整體協調人將依賴該等聲明及陳述，以決定是否就本申請向本人/我們配發任何超額預留股份，而本人/我們如作出虛假聲明，則可能會被檢控；
- 授權** 貴公司將本人/我們的姓名/名稱列入 貴公司股東名冊內，作為本人/我們獲配發的任何超額預留股份的持有人，及根據 貴公司組織章程細則規定的其他登記冊內，並按本申請表格上所示地址以普通郵遞方式向本人/我們寄發任何股票(如適用)及/或任何退款支票(如適用)，郵誤風險概由本人/我們自行承擔，除非本人/我們申請100,000股或以上超額預留股份，且本人/我們符合資格按本申請表格所述親自領取任何股票及/或任何退款支票(如適用)；
- 承諾**簽署所有文件並進行所有必要的事宜，以及根據 貴公司組織章程細則規定讓本人/我們登記為本人/我們獲分配超額預留股份的持有人；
- 要求**任何退款支票以本人/本申請表格內我們的排名首位者(倘屬聯名申請人)為抬頭人；

- **have** read the terms and conditions and application procedures set out on the pages attached to this Application Form and in the Prospectus and agree to be bound by them, and am aware of the restrictions on the Preferential Offering described in the Prospectus;
 - **represent, warrant and undertake** that the allotment of, or application for, the excess Reserved Shares would not require the Company, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters or the Capital Market Intermediaries to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong;
 - **represent, warrant and undertake** that I am not/we are not restricted by any applicable laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allotted or taking up any excess Reserved Shares; that I/we understand that the excess Reserved Shares have not been and will not be registered under the U.S. Securities Act; and that I/we will acquire the excess Reserved Shares in an “**offshore transaction**” (within the meaning of Regulation S); and
 - **agree** that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.
- 已細閱本申請表格隨附各頁及招股章程所載的條款和條件及申請程序並同意受其約束，且知悉招股章程所述有關優先發售的限制；
 - **聲明、保證及承諾**獲配發或申請認購超額預留股份不會引致 貴公司、聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人、聯席牽頭經辦人、包銷商或資本市場中介人須遵從香港以外任何地區的任何法律或法規的任何規定(不論是否具法律效力)；
 - **聲明、保證及承諾**本人/我們並非香港或其他地區任何適用法律規定不得作出是項申請、支付任何申請款項或獲配發或接納任何超額預留股份的受限制人士；及本人/我們明白超額預留股份並無亦將不會根據美國證券法登記，而本人/我們將在「離岸交易」(定義見S規例)中購買超額預留股份；及
 - 同意本申請、任何對本申請的接納以及因此訂立的合約，將受香港法例規管及按其詮釋。

Warning:

- It is important that you read the terms and conditions and application procedures overleaf.
- You must sign this application in writing (and not by way of personal chop), otherwise the application is liable to be rejected.
- Only one application may be made for the benefit of any person for excess Reserved Shares on a **BLUE** Application Form. The following are liable to be rejected: multiple or suspected multiple applications for excess Reserved Shares and applications where cheques or banker's cashier orders are dishonoured upon the first presentation.
- You may be prosecuted if you make a false declaration.
- All information stated in this Application Form must be the same as that maintained by Luye Pharma Group Ltd. or any of its wholly-owned subsidiaries.
- **You must complete this application in English in BLOCK letters (except Chinese name) unless otherwise stated, otherwise the application is liable to be rejected.**
- Any alteration to any application detail that you provide on this Application Form should be authorized by the signature of the applicant.
- You or, if you are joint applicants, the first-named applicant must provide your Hong Kong identity card number/ passport number/ Hong Kong business registration certificate number.

警告：

- 閣下必須細閱背頁的條款和條件及申請程序。
- 閣下必須以書面方式(不得以個人印章方式)簽署本申請，否則申請將被拒絕受理。
- 只可為任何人士利益以**藍色**申請表格就超額預留股份提出一次申請。下列情況將被拒絕受理：就超額預留股份提出的重複或疑屬重複申請以及支票或銀行本票在首次過戶時未能兌現的申請。
- 倘 閣下作出虛假聲明，則可遭檢控。
- 在本申請表格中聲明的所有資料必須與綠葉制藥集團有限公司或其任何全資附屬公司所保存者相同。
- 除中文姓名/名稱外，閣下必須以英文正楷填妥本申請(除非另有指明)，否則申請將被拒絕受理。
- 閣下於本申請表格提供的任何申請資料如有任何更改，應由申請人簽署授權。
- 閣下或(倘 閣下為聯名申請人)排名首位申請人必須提供香港身份證號碼/護照號碼/香港商業登記號碼。

GLOBAL OFFERING OF RESERVED SHARES
to be issued by

Shandong Boan Biotechnology Co., Ltd.
山東博安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Conditions of your Application

Unless otherwise stated, terms used in these conditions have the same meanings ascribed thereto in the Prospectus.

A. Who can apply

1. You and any person(s) for whose benefit you are applying, must be Qualifying Luye Pharma Shareholder(s) and must be 18 years of age or older and must have a Hong Kong address.
2. If you are a firm, the application must be in the individual members' names.
3. The number of joint applicants may not exceed 4.
4. If you are a body corporate, the application form must be signed by a duly authorized officer, who must state his representative capacity, and stamped with your corporation's chop.
5. You and any person(s) for whose benefit you are applying, must be outside the United States, and not be a U.S. Person (as defined in Regulation S) and not be a legal or natural person of the PRC.
6. Unless permitted by the Listing Rules, you cannot apply for any Reserved Shares if you are:
 - an existing beneficial owner of Shares in the Company and/or any of its subsidiaries;
 - a Director or chief executive officer of the Company and/or any of its subsidiaries;
 - an associate (as defined in the Listing Rules) of any of the above; or
 - a connected person (as defined in the Listing Rules) of the Company or will become a connected person of the Company immediately upon completion of the Global Offering.
 - a Non-Qualifying Luye Pharma Shareholder.

Non-Qualifying Luye Pharma Shareholders are those Luye Pharma Shareholders on the Record Date with registered addresses in any of the Specified Territories or Beneficial Luye Shareholders otherwise resident or located in a Specified Territory.

Notwithstanding any other provision in the Prospectus or the **BLUE** Application Forms, the Company reserves the right to permit any Luye Pharma Shareholder to take up his/her/its Assured Entitlement to the Reserved Shares if the Company, in its absolute discretion, is satisfied that the transaction in question is exempt from or not subject to or can otherwise be lawfully made to them without contravention of any relevant or legal regulatory requirements.

B. Allocation of Reserved Shares

A valid application for a number of Reserved Shares that is less than or equal to your Assured Entitlement will be accepted in full, subject to the terms and conditions set out in this Application Form and assuming that the conditions of the Preferential Offering are satisfied. If an application is made for a number of Reserved Shares that is less than your Assured Entitlement, you **MUST** apply for a number in one of the numbers set out in the table of numbers and payments in this Application Form and make a payment of the corresponding amount (other than HKSCC Nominees). If

you wish to apply for excess Reserved Shares in addition to your Assured Entitlement, you should complete and sign the **BLUE** Application Form for excess Reserved Shares and lodge it, together with a separate remittance for the full amount payable on application in respect of the excess Reserved Shares applied for. If an application is made for a number of Reserved Shares that is greater than your Assured Entitlement, the relevant application for Assured Entitlement will be satisfied in full, but the application for excess Reserved Shares will only be met to the extent that there are sufficient Available Reserved Shares. To the extent that excess applications for the Reserved Shares are:

- (i) less than the Available Reserved Shares, the Available Reserved Shares will first be allocated to satisfy such excess applications for the Reserved Shares in full and thereafter will be allocated, at the discretion of the Overall Coordinators, to the International Offering;
- (ii) equal to the Available Reserved Shares, the Available Reserved Shares will be allocated to satisfy such excess applications for the Reserved Shares in full; or
- (iii) more than the Available Reserved Shares, the Available Reserved Shares will be allocated on an allocation basis which will be consistent with the allocation basis commonly used in the case of over-subscriptions in public offerings in Hong Kong, where a higher allocation percentage will be applied in respect of smaller applications. If there is an odd lot number of Shares left after satisfying the excess applications, such number of odd lot Shares will be reallocated, at the discretion of the Overall Coordinators, to the International Offering.

Save for the above, the Preferential Offering will not be subject to the clawback arrangement between the International Offering and the Hong Kong Public Offering. Any application not accompanied by the correct amount of application monies will be treated as invalid in its entirety and no Reserved Shares will be allotted to such applicant.

In addition to any application for Reserved Shares under Preferential Offering made on a **BLUE** Application Form, Qualifying Luye Pharma Shareholders will be entitled to make one application for Hong Kong Offer Shares by applying through the **WHITE Form eIPO** service.

Qualifying Luye Pharma Shareholders will receive no preference as to entitlement or allocation in respect of applications for Hong Kong Offer Shares made by applying through the **WHITE Form eIPO** service under the Hong Kong Public Offering.

Qualifying Luye Pharma Shareholders are entitled to apply on the basis of an Assured Entitlement of one Reserved Share for every integral multiple of 6,638 Luye Pharma Shares held by each Qualifying Luye Pharma Shareholder on the Record Date.

Qualifying Luye Pharma Shareholders who hold less than 6,638 Luye Pharma Shares on the Record Date will not have an Assured Entitlement to the Reserved Shares, but they will still be entitled to participate in the Preferential Offering by applying for excess Reserved Shares.

C. Supplemental information

If any supplement to the Prospectus is issued, applicant(s) who have already submitted an application may or may not (depending on the information contained in the supplement) be notified that they are required to confirm their applications. If applicant(s) have been so notified but have not confirmed their applications in accordance with the procedure to be notified, all unconfirmed applications will not be valid. Subject to the above, an application once made is irrevocable and applicants shall be deemed to have applied on the basis of the Prospectus as supplemented.

D. Effect of completing and submitting this Application Form

By completing and submitting this Application Form, you (and if you are joint applicants, each of you jointly and severally) for yourself or as an agent or a nominee on behalf of each person for whom you act:

- **undertake** to execute all relevant documents and **instruct** and **authorize** the Company and/or the Overall Coordinators (or their agents or nominees), as agents of the Company, to execute any documents for you and to do on your behalf all things necessary to register any Reserved Shares allocated to you in your name as required by the Articles of Association;
- **agree** to comply with the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), and the Articles of Association;
- **confirm** that you have read the terms and conditions and application procedures set out in the Prospectus and in this Application Form and agree to be bound by them;
- **confirm** that you have received and read the Prospectus and have only relied on the information and representations contained in the Prospectus in making your application and will not rely on any other information or representations except those in any supplement to the Prospectus;
- **confirm** that you are aware of the restrictions on the Global Offering in the Prospectus;
- **agree** that none of the Company, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters, the Capital Market Intermediaries or Luye Pharma, any of their or the Company's respective directors, officers or representatives or any other parties involved in the Global Offering ("Relevant Persons") and Computershare Hong Kong Investor Services Limited ("Computershare") is or will be liable for any information and representations not in the prospectus (and any supplement to it);
- **agree** to disclose to the Company, the H Share Registrar, receiving banks and the Relevant Persons any personal data which they may require about you and the person(s) for whose benefit you have made the application;
- if the laws of any place outside Hong Kong apply to your application, **agree** and **warrant** that you have complied with all such laws and none of the Company nor the Relevant Persons will breach any law outside Hong Kong as a result of the acceptance of your offer to purchase, or any action arising from your rights and obligations under the terms and conditions contained in the Prospectus and this Application Form;
- **agree** that once your application has been accepted, you may not rescind it because of an innocent misrepresentation;
- **agree** that your application will be governed by the laws of Hong Kong;
- **represent, warrant and undertake** that (i) you understand that the Reserved Shares have not been and will not be registered under the U.S. Securities Act; and (ii) you and any person for whose benefit you are applying for the Reserved Shares are outside the United States (as defined in Regulation S);
- **warrant** that the information you have provided is true and accurate;
- **authorize** the Company to place your name(s) on the Company's register of members as the holder(s) of any Reserved Shares allocated to you, and the Company and/or its agents to send any certificate(s) and/or any refund cheque(s) to you or the first-named applicant for joint application by ordinary post at your own risk to the address stated on the application, unless you have chosen to collect the certificate(s) and/or refund cheque(s) in person;
- **understand** that Company and the Overall Coordinators will rely on your declarations and representations in deciding whether or not to make any allotment of any of the Reserved Shares to you and that you may be prosecuted for making a false declaration;
- **confirm** that you are aware of the restrictions on the Preferential Offering of the Reserved Shares as set out in the Prospectus;
- (if you are an agent for another person) **warrant** that reasonable enquiries have been made of the beneficial owner that this application is the only application which will be made for the benefit of that other person on a **BLUE** Application Form and that you are duly authorized to sign this Application Form as that other person's agent;
- **agree** that once your application is accepted, your application will be evidenced by the results of the Preferential Offering made available by the Company;
- **warrant** that, in making an application, you or any person(s) on whose behalf you may be acting is/are Qualifying Luye Pharma Shareholder(s);
- (with the exception of Directors and/or their associates who are Qualifying Luye Pharma Shareholders) **represent, warrant and undertake** that in making this application, you and/or, with the exception of HKSCC Nominees, any person(s) for whose behalf you may be acting are not connected person(s) or person(s) who will become connected person(s) of the Company immediately upon completion of the Global Offering, the subscription for Reserve Shares by you and/or, with the exception of HKSCC Nominees, any person(s) on whose behalf you may be acting is not financed directly or indirectly by a connected person of the Company, and you and/or, with the exception of HKSCC Nominees, any person(s) on whose behalf you may be acting is not taking instructions from a connected person of the Company in making this subscription for the Reserved Shares;
- **undertake and agree** to accept the Reserved Shares applied for, or any lesser number allocated to you under the application;
- **agree** with the Company and for itself and for the benefit of each holder of the Reserved Shares (and so that the Company shall be deemed by their acceptance in whole or in part of this application to have agreed, for itself and on behalf of

each holder of Reserved Shares) (and if applicable, with each CCASS Participant giving electronic application instructions), and the Company agree with each holder of the Reserved Shares, to observe and comply with Companies (Winding Up and Miscellaneous Provisions) Ordinance, the PRC Company Law and the Articles of Association of the Company;

The Company, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters, the Capital Market Intermediaries and any of their respective officers or advisers are entitled to rely on any warranty, representation or declaration made by you in this application with the exception of HKSCC Nominees. In the event of the application being made by joint applicants, all the warranties, representations, declarations and obligations expressed to be made, given or assumed by or imposed on the joint applicants shall be deemed to have been made, given and assumed by and imposed on the applicants jointly and severally. You may be prosecuted if you make a false declaration.

You must complete this application in English, unless otherwise stated, and you or (in case of joint applicants) each of the joint applicants must sign this application in writing (and not by way of personal chop), otherwise the application is liable to be rejected.

E. Power of attorney

If your application is made by a person under a power of attorney, the Overall Coordinators may accept it at their discretion, and on any conditions they think fit, including requiring evidence of the attorney's authority.

F. Offer Price

The Offer Price is HK\$19.80 per Offer Share unless otherwise announced. Applicants are required to pay the Offer Price of HK\$19.80 for each Reserved Share together with 1% brokerage, 0.0027% SFC transaction levy, 0.00015% AFRC transaction levy and 0.005% Stock Exchange trading fee.

Allotment of Reserved Shares

Subject to the terms and conditions as set out herein and in the Prospectus, the Reserved Shares will be allotted after the application lists close. The level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the Preferential Offering, and the basis of allocation of the Hong Kong Offer Shares under the Hong Kong Public Offering and the Reserved Shares under the Preferential Offering are expected to be announced on Thursday, December 29, 2022 in the websites of the Company at www.boan-bio.com and the Stock Exchange at www.hkexnews.hk. Results of allocations of the Preferential Offering, and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants (where appropriate) will be made available through various channels as described in the section headed "How to Apply for Hong Kong Offer Shares and Reserved Shares – E. Publication of Results" in the Prospectus on Thursday, December 29, 2022.

If your application for Reserved Shares is successful (in whole or in part)

If you apply for 100,000 or more Reserved Shares and have provided all information required by your Application Form, you may collect your refund cheque(s) and/or share certificate(s) from the Hong Kong Share Registrar at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Thursday, December 29, 2022 or such other date as notified by the Company in the newspapers.

If you are an individual who is eligible for personal collection, you must not authorize any other person to collect for you. If you are a corporate applicant which is eligible for personal collection, your authorized representative must bear a letter of authorization from your corporation stamped with your corporation's chop. Both individuals and authorized representatives must produce, at the time of collection, evidence of identity acceptable to the H Share Registrar.

If you do not collect your refund cheques and/or share certificate(s) personally within the time period specified for collection, it/they will be despatched promptly refund cheques and/or share certificate to the address specified in your Application Form by ordinary post at your own risk.

If you apply for less than 100,000 Reserved Shares, your refund cheque(s) and/or share certificate(s) will be sent to the address on the relevant Application Form on or before Thursday, December 29, 2022, by ordinary post and at your own risk.

The Company will not issue temporary documents of title.

Share certificates will only become valid at 8:00 a.m. on Friday, December 30, 2022 provided that the Global Offering has become unconditional and the right of termination described in the section headed "Underwriting" in the Prospectus has not been exercised. No receipt will be issued for sums paid on application. Investors who trade Shares prior to the receipt of share certificates or the share certificates becoming valid do so at their own risk.

Circumstances in which you will not be allotted Reserved Shares

You may not be allocated Reserved Shares for any of the following reasons:

1. If your application is revoked:

By completing and submitting an Application Form, you agree that your application or the application made by HKSCC Nominees on your behalf cannot be revoked on or before the expiration of the fifth day after the time of the opening of the application lists (excluding for this purpose any day which is Saturday, Sunday or public holiday in Hong Kong), unless a person responsible for the Prospectus under Section 40 of the Companies (Winding Up and Miscellaneous Provisions) Ordinance gives a public notice under that section which excludes or limits the responsibility of that person for the Prospectus. This agreement will take effect as a collateral contract with the Company, and will become binding when you lodge this Application Form. This collateral contract will be in consideration of the Company agreeing that they will not offer any Reserved Shares to any person on or before Thursday, December 29, 2022, except by means of one of the procedures referred to in the Prospectus.

If your application has been accepted, it cannot be revoked. For this purpose, acceptance of applications which are not rejected will be constituted by notification in the announcement of the results of allocation, and where such basis of allocation is subject to certain conditions or provides for allocation by ballot, such acceptance will be subject to the satisfaction of such conditions or results of the ballot, respectively.

2. **If the Company or its agents exercise their discretion to reject your application:**

The Company and the Overall Coordinators or its or their respective agents or nominees, have full discretion to reject or accept any application, or to accept only part of any application without giving any reasons.

3. **If the allotment of Reserved Shares is void:**

The allotment of Reserved Shares will be void if the Listing Committee of the Stock Exchange does not grant permission to list the Offer Shares either:

- within three weeks from the closing of the application lists; or
- within a longer period of up to six weeks if the Listing Committee notifies the Company of that longer period within three weeks of the closing date of the application lists.

4. **You will not receive any allotment if:**

- this Application Form is not completed in accordance with the instructions as stated herein;
- this Application Form has not been duly signed (only written signatures are acceptable) (or in the case of a joint application, not all applicants have signed);
- in respect of applicants who are corporate entities, this Application Form has not been duly signed (only written signature is acceptable) by an authorized officer or affixed with a company chop;
- the cheque/banker's cashier order/this Application Form is defective;
- this Application Form or either Reserved Shares pursuant to the Assured Entitlement or excess Reserved Shares is not accompanied with a cheque/banker's cashier order or is accompanied by more than one cheque/banker's cashier order for each of the application for Assured Entitlement and excess application for Reserved Shares;
- the account name on cheque/banker's cashier order is not pre-printed or certified by the issuing bank;
- the cheque/banker's cashier order is not drawn on a Hong Kong dollar bank account in Hong Kong;
- the name of the payee indicated on the cheque/banker's cashier order is not **"BANK OF CHINA (HONG KONG) NOMINEES LIMITED – BOAN BIOTECHNOLOGY PREFERENTIAL OFFER"**;
- the cheque has not been crossed "Account payee only";
- the cheque was post-dated;
- the applicant's payment is not made correctly or the applicant pays by cheque or banker's cashier order and the cheque or banker's cashier order is dishonoured on its first presentation;
- the applicant's name/the first applicant's name on the joint application is not the same as the name pre-printed or certified/endorsed by the drawee bank on the cheque/banker's cashier order;
- alteration(s) to the application details on this Application Form has not been authorized by the signature(s) of the applicant(s);
- the application is completed by pencil;
- the application does not fill in all the boxes in the option he/she/it chooses;
- the applicant chooses more than one of the options on the BLUE Application Form;

- the Company or the Directors believe that by accepting the application, the Company would violate the applicable securities or other laws, rules or regulations of the jurisdiction where this Application Form is received or where the applicant is resident or located; or the applicant has an address in such jurisdiction; or
- the Company and the Overall Coordinators, and their respective agents or nominees, exercise their discretion to reject or accept any application, or to accept only part of any application. No reasons have to be given for any rejection or acceptance.

5. If you are applying by using the BLUE Application Form for Assured Entitlement, you may apply for a number of Reserved Shares pursuant to your Assured Entitlement that is equal to or less than the number stated in Box B. If you intend to apply for a number of Reserved Shares that is less than your Assured Entitlement, you MUST apply for a number which is one of the numbers set out in the table in the BLUE Application Form and make a payment of the corresponding amount (other than HKSCC Nominees).

You need to complete and sign the BLUE Application Form for Assured Entitlement and submit one cheque (or banker's cashier order) for the exact amount of remittance printed in Box B or the corresponding amount payable as set out in the table in the BLUE Application Form. If you wish to apply for excess Reserved Shares in addition to your Assured Entitlement, you should complete and sign the BLUE Application Form for excess Reserved Shares and lodge it, together with a separate remittance for the full amount payable on application in respect of the excess Reserved Shares applied for.

6. If you are applying by using the BLUE Application Form for excess Reserved Shares, you MUST apply for a number which is one of the numbers set out in the table in the BLUE Application Form for excess Reserved Shares and make a payment of the corresponding amount (other than HKSCC Nominees). You need to complete and sign the BLUE Application Form for excess Reserved Shares and submit a separate cheque (or banker's cashier order) for the exact amount of remittance.

7. If you intend to apply for both Reserved Shares pursuant to your Assured Entitlement and excess Reserved Shares, you must submit both the BLUE Application Form for Assured Entitlement and the BLUE Application Form for excess Reserved Shares. Each BLUE Application Form must be accompanied by a separate cheque (or banker's cashier order) for the exact amount of remittance.

Refund of your money

If you do not receive any Reserved Shares or if your application is accepted only in part, the Company will refund to you your application monies (including the related 1% brokerage, 0.0027% SFC transaction levy, 0.00015% AFRC transaction levy and 0.005% Stock Exchange trading fee) or the appropriate portion thereof without interest. The refund procedures are stated in the "G. Refund of Application Monies" in the "How to Apply for Hong Kong Offer Shares and Reserved Shares" section of the Prospectus.

Effect of the Information You Give to Computershare Hong Kong Investor Services Limited

Computershare Hong Kong Investor Services Limited and its related bodies' corporate, directors, officers, employees and agents ("Representatives") expressly disclaim and exclude to the maximum extent permitted by law any liability for any loss or damage suffered or incurred by the applicant or any other person or entity however caused relating in any way to, or connected with, any information provided by or on behalf of the applicant on or in connection with this document or any services provided hereunder, or any other written or oral

communication provided by or on behalf of the applicant in connection with this document or any services provided hereunder. This includes, without limitation, any errors or omissions in such information however caused, or the Representatives or any other person or entity placing any reliance on such information or any documentation, image, recording or reproduction of such information, or its accuracy, completeness, currency or reliability.

By signing this Application Form, you agree to all of the above.

How to make your application

1. **If you are applying by using the BLUE Application Form for Assured Entitlement**, you may apply for a number of Reserved Shares pursuant to your Assured Entitlement that is equal to or less than the number stated in Box B in the Application Form. If you intend to apply for a number of Reserved Shares that is less than your Assured Entitlement, you **MUST** apply for a number which is one of the numbers set out in the table in the **BLUE** Application Form for Assured Entitlement, you should (i) write the number of Reserved Shares applied for and the amount payable (as set out in the table in the Application Form); (ii) complete and sign the Application Form; and (iii) submit one cheque (or banker's cashier order) for the same amount that you have written in the Application Form (other than HKSCC Nominees). If you wish to apply for excess Reserved Shares in addition to your Assured Entitlement, you should complete and sign the **BLUE** Application Form for excess Reserved Shares and lodge it, together with a separate remittance for the full amount payable on application in respect of the excess Reserved Shares applied for. If you intend to apply for a number of Reserved Shares that is equal to your Assured Entitlement, you should (i) complete and sign the Application Form and (ii) submit one cheque (or banker's cashier order) for the exact amount of remittance printed in Box B in the Application Form.

If you are applying by using the BLUE Application Form for excess Reserved Shares, you should (i) write the number of excess Reserved Shares applied for and the amount payable (as set out in the table on the Application Form); (ii) complete and sign the Application Form; and (iii) submit one separate cheque (or banker's cashier order) for the same amount that you have written on the Application Form. The number of excess Reserved Shares that you intend to apply for **MUST** be one of the numbers set out in the table in the Application Form for excess Reserved Shares (other than HKSCC Nominees).

2. Complete the form and sign it. **Only written signatures will be accepted.**

3. Staple your cheque or bank's cashier order to the form. You must pay for the application for Assured Entitlement by one **cheque** or by one **banker's cashier order** and/or pay for the application for excess Reserved Shares by one **cheque** or by one **banker's cashier order**. Each application must be accompanied by either a separate cheque or banker's cashier order.

If you pay by cheque, the cheque must:

- be in Hong Kong dollars;
- be drawn on your Hong Kong dollar bank account in Hong Kong;
- show your account name. This name must either be preprinted on the cheque, or be endorsed at the back by a person authorized by the bank. This account name must be the same name as the name on this form. If it is a joint application, the account name must be the same as the name of the first-named applicant;
- be made payable to "**BANK OF CHINA (HONG KONG) NOMINEES LIMITED – BOAN BIOTECHNOLOGY PREFERENTIAL OFFER**";
- be crossed "Account Payee Only"; and
- not be post-dated.

Your application may be rejected if your cheque:

- does not meet all these requirements; or
- is dishonoured on its first presentation.

If you pay by banker's cashier order, the cashier order must:

- be in Hong Kong dollars;
- be issued by licensed banks in Hong Kong, and have your name certified at the back of the order by a person authorized by the bank. The name on the back of the order and the name on this Application Form must be the same. If it is a joint application, the name at the back of the order must be the same as the name of the first-named applicant;
- be made payable to "**BANK OF CHINA (HONG KONG) NOMINEES LIMITED – BOAN BIOTECHNOLOGY PREFERENTIAL OFFER**";
- be crossed "Account Payee Only"; and
- not be post-dated.

Your application is liable to be rejected if your cheque or banker's cashier order does not meet all these requirements.

4. This Application Form, together with your cheque or a banker's cashier order attached, should be deposited in the special collection boxes provided at Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong. This Application Form can be lodged at these times:
- | | | |
|------------------------------|---|-------------------------|
| Monday, December 19, 2022 | — | 9:00 a.m. to 4:30 p.m. |
| Tuesday, December 20, 2022 | — | 9:00 a.m. to 4:30 p.m. |
| Wednesday, December 21, 2022 | — | 9:00 a.m. to 4:30 p.m. |
| Thursday, December 22, 2022 | — | 9:00 a.m. to 12:00 noon |
5. The latest time for lodging your application is 12:00 noon on Thursday, December 22, 2022 or, if the application lists are not open on that day, then by 12:00 noon on the next day the lists are open. The application lists will be open between 11:45 a.m. and 12:00 noon on that day, subject only to weather conditions. The application lists will not open if there are:
- a tropical cyclone warning signal 8 or above
 - Extreme Conditions; and/or
 - a "black" rainstorm warning
- in force in Hong Kong at any time between 9:00 a.m. and 12:00 noon on Thursday, December 22, 2022. Instead they will be open between 11:45 a.m. and 12:00 noon on the next business day which does not have any of those warnings or Extreme Conditions in Hong Kong in force at any time between 9:00 a.m. and 12:00 noon. Business day means a day that is not a Saturday, Sunday or public holiday in Hong Kong.
6. **The application monies (including the brokerage fees, SFC transaction levies, AFRC transaction levy and Stock Exchange trading fees) will be held by the receiving banks and on behalf of the Company after the closing of the application lists and the refund monies, if any, will be returned to the applicants without interest on or before Thursday, December 29, 2022. Investors should be aware that the dealings in the Offer Shares on the Stock Exchange are expected to commence on Friday, December 30, 2022.**
7. **The right is reserved to present all or any remittances for payment. However, your cheque or banker's cashier order will not be presented for payment before 12:00 noon on Thursday, December 22, 2022. You will not be given a receipt for your payment. The Company will retain any interest accrued on your application monies. The right is also reserved to retain any Share certificate(s) and/or any surplus application money(ies) or refunds pending clearance of your cheque or banker's cashier order.**

全球發售
由本公司發行的預留股份

Shandong Boan Biotechnology Co., Ltd.
山東博安生物技術股份有限公司
(於中華人民共和國註冊成立的股份有限公司)

全球發售

申請條件

除另有指明外，此等條件所用詞彙具備招股章程所賦予的相同涵義。

甲. 可提出申請的人士

- 閣下及閣下為其利益提出申請的人士必須為合資格綠葉製藥股東及年滿18歲並有香港地址。
- 如閣下為商號，申請須以個別成員名義提出。
- 聯名申請人不得超過四名。
- 如閣下為法人團體，申請表須經獲正式授權人員簽署，並註明其所屬代表身份及蓋上公司印鑑。
- 閣下及閣下為其利益提出申請的人士必須身處美國境外，並非美國人(定義見S規例)，亦非中國法人或自然人。
- 除上市規則批准外，下列人士概不得申請認購任何預留股份：
 - 本公司及／或其任何附屬公司股份的現有實益擁有人；
 - 本公司及／或其任何附屬公司的董事或最高行政人員；
 - 上述任何人士的聯繫人(定義見上市規則)；或
 - 本公司的關連人士(定義見上市規則)或緊隨全球發售完成後成為本公司的關連人士。
 - 不合資格綠葉製藥股東。

不合資格綠葉製藥股東為於記錄日期其登記地址位於任何特定地區的綠葉製藥股東，或任何居於或身處特定地區的實益綠葉股東。

不論招股章程或藍色申請表格的任何其他條文，倘本公司全權酌情信納有關交易獲豁免或毋須遵守任何相關或法定監管要求或可以其他方式向彼等合法作出而不會違反任何相關或法定監管要求，則本公司保留權利允許任何綠葉製藥股東接納其預留股份的保證配額。

乙. 分配預留股份

在本申請表格所載條款及條件的規限下，並假設優先發售的條件獲達成，申請少於或相等於閣下保證配額數目的預留股份的有效申請將獲全數接納。倘申請的預留股份數

目少於閣下的保證配額，閣下必須申請本申請表格內數目及款項一覽表所列的其中一個數目並支付相應款額(香港結算代理人除外)。倘閣下擬申請閣下保證配額以外的超額預留股份，則閣下應填妥及簽署藍色申請表格申請超額預留股份，並連同申請時就所申請超額預留股份而另行應付的足額股款一併交回。倘申請的預留股份數目多於閣下的保證配額，有關保證配額的申請將獲悉數接納，但超額預留股份的申請將僅在有足夠可用預留股份的情況下會獲接納。倘預留股份的超額申請：

- 少於可用預留股份，則可用預留股份的分配將首先全數滿足該等預留股份的超額申請，其後將由整體協調人酌情分配至國際發售；
- 相等於可用預留股份，則可用預留股份的分配將全數滿足該等預留股份的超額申請；或
- 多於可用預留股份，則可用預留股份的分配將與香港公開發售超額認購下常用的分配基準一致的分配基準作出，即預留股份超額申請數目較少的申請人可獲較高的分配百分比。倘滿足超額申請後有任何零碎股份，有關零碎股份將由整體協調人酌情重新分配至國際發售。

除上述者外，優先發售將不受國際發售與香港公開發售之間的回撥安排所規限。未隨附正確金額申請款項的任何申請將視為完全無效且不會向有關申請人配發任何預留股份。除以藍色申請表格申請優先發售項下的預留股份外，合資格綠葉製藥股東亦可透過白表eIPO服務作出一份香港發售股份申請。

合資格綠葉製藥股東根據香港公開發售透過白表eIPO服務申請香港發售股份，在配額或分配方面並無優先權。

合資格綠葉製藥股東可按其各自於記錄日期每持有6,638股綠葉製藥股份的完整倍數獲發保證配額一股預留股份的基準提出申請。

於記錄日期持有少於6,638股綠葉製藥股份的合資格綠葉製藥股東將不會享有預留股份的保證配額，但仍有權通過申請超額預留股份參與優先發售。

丙. 補充資料

如就招股章程刊發任何補充文件，已遞交申請的申請人未必會獲通知(取決於補充文件所載資料)，要求彼等確認其申請。如申請人接獲通知但並無根據所獲通知的程序確認其申請，所有未獲確認的申請將會無效。受上文所規限，申請一經提交即不得撤銷，而申請人將視為根據已按經補充的招股章程提出申請。

丁. 填交本申請表格的效用

閣下填妥並遞交本申請表格，即表示閣下(如屬聯名申請人，即各人共同及個別)代表閣下本身，或作為閣下代其行事的每位人士的代理或代名人：

- **承諾**簽立所有相關文件，並指示及授權本公司及/或作為本公司代理的整體協調人(或其代理或代名人)，按照組織章程細則的規定將閣下獲分配的任何預留股份以閣下名義登記而代表閣下簽立任何文件及代表閣下進行一切必需事宜；
- **同意**遵守香港法例第622章公司條例、香港法例第32章公司(清盤及雜項條文)條例及組織章程細則；
- **確認**閣下已閱讀招股章程及本申請表格所載的條款及條件以及申請程序，並同意受其約束；
- **確認**閣下已接獲及閱讀招股章程，並於作出申請時僅依賴招股章程所載資料及陳述，閣下不會依賴任何其他資料或陳述(招股章程任何補充文件所載者除外)；
- **確認**閣下知悉招股章程內有關全球發售的限制；
- **同意**本公司、聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人、聯席牽頭經辦人、包銷商、資本市場中介人或綠葉製藥、任何彼等或本公司各自的董事、高級職員、或代表或參與全球發售的任何其他各方(「相關人士」)及香港中央證券登記有限公司(「中央證券」)現時或日後均毋須對並非載於招股章程(及其任何補充文件)的任何資料及陳述負責；
- **同意**向本公司、H股證券登記處、收款銀行及相關人士披露其可能要求提供有關閣下及閣下為其利益提出申請的人士的任何個人資料；
- 倘香港境外任何地方的法律適用於閣下的申請，則**同意及保證**閣下已遵守所有有關法律，而本公司及相關人士概不會因接納閣下的購買要約，或因閣下於招股章程及本申請表格所載條款及條件項下權利及責任所引致的任何行動，而違反香港境外的任何法律；

- **同意**閣下的申請一經接納，即不得因無意的失實陳述而撤銷；
- **同意**閣下的申請受香港法例規管；
- **聲明、保證及承諾**(i) 閣下明白預留股份未曾亦不會根據美國證券法登記；及(ii) 閣下及閣下為其利益申請預留股份的任何人士均身處美國境外(定義見S規例)；
- **保證**閣下提供的資料真實準確；
- **授權**本公司將閣下的姓名/名稱列入本公司股東名冊，作為閣下獲分配預留股份的持有人及本公司及/或其代理將任何股票及/或任何退款支票，以普通郵遞方式按申請所列的地址寄發予閣下或(如屬聯名申請)排名首位的申請人，郵誤風險概由閣下自行承擔，除非閣下選擇親身領取股票及/或退款支票；
- **明白**本公司及整體協調人將依賴閣下的聲明及陳述，以決定是否向閣下配發任何預留股份，而閣下如作出虛假聲明，則可能會被檢控；
- **確認**閣下知悉招股章程所述有關預留股份的優先發售限制；
- (如閣下為他人的代理)**保證**已向實益擁有人作出合理查詢，確認本申請乃為該人士利益以藍色申請表格而提出的唯一申請，而閣下已獲正式授權，以該人士代理的身份簽署本申請表格；
- **同意**一旦閣下的申請獲接納，閣下的申請將以本公司發出的優先發售結果為證；
- **保證**在提出申請時，閣下或閣下可能代其行事的任何人士為合資格綠葉製藥股東；
- (身為合資格綠葉製藥股東的董事及/或彼等的聯繫人除外)**聲明、保證及承諾**，在提出本申請時，閣下及/或(香港結算代理人除外)閣下可能代其行事的任何人士並非關連人士，亦並非將在緊隨全球發售完成後成為本公司關連人士的人士，而閣下及/或(香港結算代理人除外)閣下可能代其行事的任何人士認購預留股份並非直接或間接由本公司的關連人士提供資金，且閣下及/或(香港結算代理人除外)閣下可能代其行事的任何人士並非根據本公司關連人士的指示作出預留股份的是次認購；
- **承諾並同意**接納所申請的預留股份，或閣下根據申請所獲分配的任何較少數目；
- 向本公司表示**同意**(及從而使本公司(為其本身並代表各預留股份持有人)藉其接納全部或部分本申請而視為已同意)(及(如適用)向發出電子認購指示的各中央結

算系統參與者表示同意)，以及本公司向各預留股份持有人表示同意，遵守及符合公司(清盤及雜項條文)條例、中國公司法以及本公司組織章程細則；

除香港結算代理人外，本公司、聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人、聯席牽頭經辦人、包銷商、資本市場中介人及彼等各自的任何高級職員或顧問均有權依賴閣下在申請中作出的任何保證、陳述或聲明。如為聯名申請人提出申請，聯名申請人明確作出、提供、承擔或被施加的所有保證、陳述、聲明及責任將視為由申請人共同及個別地作出、提供、承擔及被施加。閣下如作出虛假聲明，可能會遭檢控。

除非另有訂明，否則閣下必須以英文填妥申請，否則申請將被拒絕受理。閣下或(如為聯名申請人)各聯名申請人必須親自簽署申請，不得以個人印章代替，否則申請將被拒絕受理。

戊. 授權書

如申請由獲得授權書正式授權的人士提出，則整體協調人可在申請符合彼等認為合適的條件下(包括出示授權證明)，酌情接納有關申請。

己. 發售價

除非另有公佈，否則發售價為每股發售股份19.80港元。申請人須繳付發售價每股預留股份19.80港元，另加1%經紀佣金、0.0027%證監會交易徵費、0.00015%會財局交易徵費及0.005%聯交所交易費。

預留股份的配發

在本申請表格及招股章程載列的條款及條件規限下，預留股份將於截止辦理申請登記後配發。預期國際發售的認購踴躍程度、香港公開發售及優先發售的認購申請水平以及香港公開發售項下的香港發售股份及優先發售項下的預留股份的分配基準將於2022年12月29日(星期四)在本公司網站 www.boan-bio.com 及聯交所網站 www.hkexnews.hk 公佈。優先發售的分配結果，以及成功申請人的香港身份證/護照/香港商業登記號碼(如適用)，將於2022年12月29日(星期四)通過招股章程「如何申請香港發售股份及預留股份—E.公佈結果」一節所述的多個渠道公佈。

如 閣下成功申請認購預留股份(全部或部分)

倘閣下申請100,000股或以上預留股份並已提供申請表格規定的全部資料，則閣下可於2022年12月29日(星期四)或本公司於報章公佈的其他日期上午九時正至下午一時正自本公司香港證券登記處(地址為香港灣仔皇后大道東183號合和中心17樓1712-1716號舖)領取退款支票及/或股票。

如閣下為個人申請人並合資格親身領取，閣下不得授權任何其他人士代為領取。如閣下為公司申請人並合資格親身領取，閣下的授權代表須攜同蓋上公司印鑑的授權書領取。個人及授權代表均須於領取時出示H股證券登記處接納的身份證明文件。

如閣下並無在指定領取時間內親身領取退款支票及/或股票，有關支票及/或股票將立刻以普通郵遞方式寄往閣下申請表格所示地址，郵誤風險概由閣下自行承擔。

倘閣下申請少於100,000股預留股份，則閣下的退款支票及/或股票將於2022年12月29日(星期四)或之前以普通郵遞方式寄往相關申請表格所示地址，郵誤風險概由閣下自行承擔。本公司不會發出臨時所有權文件。

於全球發售已成為無條件及招股章程「包銷」一節所述終止權利未有行使的情況下，股票方會於2022年12月30日(星期五)上午八時正生效。概不會就申請時支付的款項發出收據。投資者如於獲發股票前或股票生效前買賣股份，須自行承擔一切風險。

閣下不獲配發預留股份的情況

閣下可能基於下列任何理由而不獲分配預留股份：

1. 倘 閣下的申請被撤回：

填妥及遞交申請表格，即表示閣下的申請或香港結算代理人代表閣下提出的申請不得於開始辦理申請登記時間後第五日(不包括為星期六、星期日或香港公眾假期的任何日子)或之前撤回，除非根據公司(清盤及雜項條文)條例第40條對招股章程負責的人士根據該條規例發出公告，免除或限制該人士對招股章程所負責任。此協議將成為本公司訂立的附屬合約，並在閣下遞交本申請表格時即具約束力。該附屬合約的代價為本公司同意，除按招股章程所述任何一項程序外，不會於2022年12月29日(星期四)或之前向任何人士提呈發售任何預留股份。

閣下的申請一經接納，即不得撤回。就此而言，於公告公佈分配結果即構成接納未被拒絕的申請，而倘有關分配基準受若干條件規限或規定以抽籤方式分配，則該項接納將分別視乎有關條件能否達成或抽籤結果而定。

2. 倘本公司或其代理行使酌情權拒絕受理 閣下的申請：

本公司及整體協調人或其或彼等各自的代理人或代名人可全權酌情拒絕或接納任何申請，或僅接納任何部分申請，而毋須提供任何理由。

3. 倘預留股份的配發作廢：

倘聯交所上市委員會在下列期間並無批准發售股份上市，則預留股份的配發將告作廢：

- 自截止辦理申請登記日期起三個星期內；或
- 倘上市委員會在截止辦理申請登記日期起三個星期內通知本公司延長有關期間，則於最多達六個星期的較長期間。

4. 在下列情況下， 閣下將不獲任何配發：

- 本申請表格並無遵照本申請表格所載指示填妥；
- 本申請表格並無正式簽署(僅接受親筆簽署)(或如屬聯名申請，並非所有申請人均已簽署)；
- 就屬於公司實體的申請人而言，本申請表格並未經獲授權人員正式簽署(僅接受親筆簽署)或加蓋公司印鑑；
- 支票／銀行本票／本申請表格有缺陷；
- 根據保證配額申請預留股份或超額預留股份的本申請表格並無附上支票／銀行本票或就申請保證配額及超額申請預留股份附上多於一張支票／銀行本票；
- 支票／銀行本票上的賬戶名稱並非預印或經發行銀行核證；
- 支票／銀行本票並非由香港的港元銀行賬戶開出；
- 支票／銀行本票的抬頭人並非「中國銀行(香港)代理有限公司－博安生物技术優先發售」；
- 支票並無劃線註明「只准入抬頭人賬戶」；
- 該支票為期票；
- 申請人的付款方式不正確，或申請人以支票或銀行本票付款但該支票或銀行本票在首次過戶時未能兌現；
- 申請人姓名／聯名申請的首名申請人姓名與支票／銀行本票上預印或付款銀行核證／背書的姓名／名稱不同；
- 本申請表格申請詳情的任何更改未獲申請人的簽署授權；
- 申請以鉛筆填寫；
- 並無填寫申請選項的所有空格；
- 申請人於藍色申請表格中選擇超過一個選項；

- 本公司或董事認為接納申請將違反收取本申請表格或申請人居於或身處或地址所在司法權區的適用證券或其他法例、規則或規定；或

- 本公司及整體協調人及彼等各自的代理或代名人可酌情拒絕或接納任何申請，或僅接納任何部分的申請。毋須就拒絕或接納任何申請解釋原因。

5. 倘 閣下使用藍色申請表格申請保證配額，則 閣下可根據保證配額申請相等於或少於乙欄所列數目的預留股份。倘 閣下擬申請的預留股份數目少於 閣下的保證配額，則 閣下必須申請藍色申請表格一覽表所列其中一個數目，並支付相應款項(香港結算代理人除外)。

閣下須填妥及簽署保證配額的藍色申請表格，並提交一張支票(或銀行本票)，金額為藍色申請表格乙欄所印備的確切匯款金額或藍色申請表格一覽表所載的相應應付款項。倘 閣下擬申請 閣下保證配額以外的超額預留股份，則 閣下應填妥及簽署藍色申請表格申請超額預留股份，並連同申請時就所申請超額預留股份而另行應付的足額股款一併交回。

6. 倘 閣下使用藍色申請表格申請超額預留股份， 閣下必須申請超額預留股份的藍色申請表格一覽表所列其中一個數目，並支付相應款項(香港結算代理人除外)。 閣下須填妥及簽署超額預留股份的藍色申請表格，並提交確切股款金額的一張獨立支票(或銀行本票)。

7. 倘 閣下擬同時申請保證配額的預留股份及超額預留股份，則必須同時遞交保證配額的藍色申請表格及超額預留股份的藍色申請表格。每份藍色申請表格必須隨附確切股款金額的獨立支票(或銀行本票)。

退回款項

倘 閣下未獲分配任何預留股份或申請僅部分獲接納，本公司將不計息退還 閣下的申請股款(包括有關的1%經紀佣金、0.0027%證監會交易徵費、0.00015%會財局交易徵費及0.005%聯交所交易費)或其中適當部分。有關退款程序載於招股章程「如何申請香港發售股份及預留股份」一節「G.退還申請股款」。

閣下提供給香港中央證券登記有限公司的資訊的有關影響

香港中央證券登記有限公司和其有關連的法人團體、董事、高級人員、僱員及代理人(「代表」)在法律所容許的最大限度內明確卸棄及免除在任何方面與申請人或代表申請人在此文件提供的或與此文件或在此文件下提供的任何服務相關的任何資料，或任何申請人或代表申請人提供與此文件或在此文件下提供的任何服務相關的任何其他書面或口頭通訊，有關或相關由申請

人或任何其他人士或實體所遭受或招致不論如何造成的任何損失或損害的任何法律責任。此包括，但不限於，該等資料中不論如何造成的任何錯誤或遺漏，或代表或任何其他人士或實體對該等資料或任何該等資料的文件記錄、影像、記錄或複製品作出的任何依據，或其準確性、完整性、合時性或可靠性。

閣下簽署本申請表格，即表示同意上述各項。

申請程序

1. 倘閣下使用藍色申請表格申請保證配額，則閣下可根據保證配額申請相等於或少於藍色申請表格乙欄所列數目的預留股份。倘閣下擬申請的預留股份數目少於閣下的保證配額，則閣下必須申請藍色申請表格預留股份一覽表所列其中一個數目，閣下應：(i)填妥所申請的預留股份數目及應付金額(申請表格一覽表所載者)；(ii)填妥並簽署申請表格；及(iii)提交一張支票(或銀行本票)，金額須為閣下在申請表格填寫的相同金額(香港結算代理人除外)。倘閣下擬申請保證配額以外的超額預留股份，則閣下應填妥及簽署藍色申請表格申請超額預留股份，並連同申請時就所申請超額預留股份而另行應付的足額股款一併交回。倘閣下擬申請相等於閣下保證配額的預留股份數目，閣下應：(i)填妥並簽署申請表格；及(ii)提交一張支票(或銀行本票)，金額須為申請表格乙欄所列明的確切金額。

倘閣下使用藍色申請表格申請超額預留股份，閣下應：(i)填寫所申請的超額預留股份數目及應付金額(申請表格一覽表所載者)；(ii)填妥並簽署申請表格；及(iii)提交一張獨立開出的支票(或銀行本票)，金額須為閣下在申請表格填寫的相同金額。閣下擬申請的超額預留股份數目必須為申請表格申請超額預留股份一覽表所載數目之一(香港結算代理人除外)。

2. 請填妥並簽署申請表格。僅接納親筆簽名。
3. 支票或銀行本票須緊釘於表格。閣下必須以一張支票或一張銀行本票支付保證配額的申請款項及／或以一張支票或一張銀行本票支付超額預留股份的申請款項。每份申請均須附帶一張獨立支票或銀行本票。

如以支票繳付款項，該支票必須：

- 為港元支票；
- 由香港的港元銀行賬戶開出；
- 顯示閣下的賬戶名稱，而該戶名必須預印於支票，或由有關銀行授權人在該支票背面簽署證明戶名。該賬戶名稱必須與閣下於本表格上的姓名／名稱相同。如屬聯名申請，則賬戶名稱必須與排名首位申請人的姓名／名稱相同；
- 註明抬頭人為「中國銀行(香港)代理人有限公司－博安生物技术優先發售」；
- 劃線註明「只准入抬頭人賬戶」；及
- 不得為期票。

下列情況將導致申請可能被拒絕受理：

- 支票不符合所有上述規定；或
- 支票首次過戶時不獲兌現。

如以銀行本票繳付款項，該本票必須：

- 為港元；
- 由香港持牌銀行發出，並由發出本票銀行的授權人在本票背面簽署證明閣下姓名。本票背面所顯示姓名須與本申請表格所填寫的姓名／名稱相同。如屬聯名申請，本票背面所示姓名／名稱必須與排名首位申請人的姓名／名稱相同；
- 註明抬頭人為「中國銀行(香港)代理人有限公司－博安生物技术優先發售」；
- 劃線註明「只准入抬頭人賬戶」；及
- 不得為期票。

如閣下的支票或銀行本票不符合上述所有規定，則閣下的申請可能遭拒絕受理。

4. 本申請表格連同 閣下的支票或銀行本票，應投入香港中央證券登記有限公司(地址為香港灣仔皇后大道東183號合和中心17M樓)提供的特備收集箱。 閣下可於下列時間遞交本申請表格：
- 2022年12月19日(星期一) 一上午九時正至下午四時半
2022年12月20日(星期二) 一上午九時正至下午四時半
2022年12月21日(星期三) 一上午九時正至下午四時半
2022年12月22日(星期四) 一上午九時正至中午十二時正
5. 遞交申請的截止時間是2022年12月22日(星期四)中午十二時正，如該日並無開始登記認購申請，則為下一日開始登記認購申請的中午十二時正。本公司將於當日上午十一時四十五分至中午十二時正期間登記認購申請，惟須視乎當日天氣情況而定。倘香港於2022年12月22日(星期四)上午九時正至中午十二時正期間任何時間發出：
- 八號或以上熱帶氣旋警告信號；
 - 極端情況；及/或
 - 「黑色」暴雨警告，
- 則不會開始辦理申請登記，而改為於下一個上午九時正至中午十二時正期間任何時間在香港並無發出該等警告信號或極端情況的營業日上午十一時四十五分至中午十二時正期間開始辦理申請登記。
- 營業日指星期六、星期日或香港公眾假期以外的日子。
6. 申請股款(包括經紀佣金、證監會交易徵費、會財局交易徵費及聯交所交易費)將由收款銀行於截止辦理申請登記後代表本公司持有，且退款金額(如有)將於2022年12月29日(星期四)或之前不計利息退還予申請人。投資者務請注意，預期發售股份將於2022年12月30日(星期五)於聯交所開始買賣。
7. 本公司保留將 閣下的一切或任何股款過戶的權利，然而， 閣下的支票或銀行本票不會於2022年12月22日(星期四)中午十二時正前過戶。 閣下不會就已繳付款項獲發收據。本公司將保留 閣下的申請款項的任何應得利息。在 閣下的支票或銀行本票過戶前，本公司亦有權保留任何股票及/或任何多收的申請款項或退款。

Personal Data**Personal Information Collection Statement**

This Personal Information Collection Statement informs the applicant for, and holder of, Hong Kong Offer Shares, of the policies and practices of the Company and its Hong Kong Share Registrar in relation to personal data and the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the “Ordinance”).

1. Reasons for the collection of your personal data

It is necessary for applicants and registered holders of securities to supply correct personal data to the Company or its agents and the Hong Kong Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the Hong Kong Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected, or in delay or the inability of the Company or its Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfers of the Hong Kong Offer Shares which you have successfully applied for and/or the dispatch of share certificate(s) and/or refund cheque(s) to which you are entitled.

It is important that securities holders inform the Company and the Hong Kong Share Registrar immediately of any inaccuracies in the personal data supplied.

2. Purposes

The personal data of the securities holders may be used, held, processed, and/or stored (by whatever means) for the following purposes:

- processing your application and refund cheque, where applicable, verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- compliance with applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of securities’ holders including, where applicable, HKSCC Nominees;
- maintaining or updating the register of securities’ holders of the Company;
- verifying securities holders’ identities;
- establishing benefit entitlements of securities’ holders of the Company, such as dividends, rights issues and bonus issues, etc.;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and securities’ holders profiles;
- disclosing relevant information to facilitate claims on entitlements; and

- any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to securities’ holders and/or regulators and/or any other purposes to which the securities’ holders may from time to time agree.

3. Transfer of personal data

Personal data held by the Company and its Hong Kong Share Registrar relating to the securities holders will be kept confidential but the Company and its Hong Kong Share Registrar may, to the extent necessary for achieving any of the above purposes, disclose, obtain or transfer (whether within or outside Hong Kong) the personal data to, from or with any of the following:

- the Company’s appointed agents such as financial advisers, receiving bankers and overseas principal share registrar;
- where applicants for securities request a deposit into CCASS, HKSCC or HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company or the Hong Kong Share Registrar in connection with their respective business operation;
- the Hong Kong Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any persons or institutions with which the securities’ holders have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers etc.

4. Retention of personal data

The Company and its Hong Kong Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5. Access to and correction of personal data

Securities holders have the right to ascertain whether the Company or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. The Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of such requests.

All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the section headed “Corporate Information” of the Prospectus or as notified from time to time, for the attention of the company secretary, or our Hong Kong Share Registrar for the attention of the privacy compliance officer.

By signing an Application Form or by giving electronic application instructions to HKSCC, you agree to all of the above.

個人資料

個人資料收集聲明

此個人資料收集聲明旨在向香港發售股份的申請人及持有人說明有關本公司及其香港證券登記處有關個人資料及香港法例第486章個人資料(私隱)條例(「條例」)方面的政策及慣例。

1. 收集 閣下個人資料的原因

證券申請人及登記持有人以本身名義申請證券或轉讓或受讓證券時或尋求香港證券登記處的服務時，必須向本公司或代理人及香港證券登記處提供準確個人資料。

未能提供所要求的資料可能導致 閣下的證券申請被拒或延遲，或本公司或其香港證券登記處無法落實轉讓或以其他方式提供服務。此舉亦可能妨礙或延遲登記或轉讓 閣下成功申請的香港發售股份及／或寄發 閣下應得的股票及／或退款支票。

證券持有人所提供的個人資料如有任何錯誤，須立即通知本公司及香港證券登記處。

2. 目的

閣下的個人資料可以任何方式被使用、持有、處理及／或保存，以作下列用途：

- 處理 閣下的申請及退款支票(如適用)，核實是否符合本申請表格及招股章程載列的條款及申請程序以及公佈香港發售股份的分配結果；
- 遵守香港及其他地區的適用法律及法規；
- 以證券持有人(包括香港結算代理人(如適用))的名義登記新發行證券或轉讓或受讓證券；
- 存置或更新本公司證券持有人的名冊；
- 核實證券持有人的身份；
- 確定證券持有人的受益權利，例如股息、供股及紅股發行等；
- 分發本公司及其附屬公司的通訊；
- 編製統計資料及證券持有人資料；
- 披露有關資料以便就權益提出申索；及

- 與上述有關的任何其他附帶或相關目的及／或使本公司及香港證券登記處能履行對證券持有人及／或監管機構承擔的責任及／或證券持有人不時同意的任何其他目的。

3. 轉交個人資料

本公司及其香港證券登記處所持有關證券持有人的個人資料將會保密，但本公司及其香港證券登記處可在為達到上述任何目的之必要情況下，向下列任何人士披露、獲取或轉交(無論在香港境內或境外)有關個人資料：

- 本公司委任的代理人，例如財務顧問、收款銀行及主要海外股份過戶登記處；
- (如證券申請人要求將證券存於中央結算系統)香港結算或香港結算代理人，彼等將會就中央結算系統的運作使用有關個人資料；
- 向本公司或香港證券登記處提供與其各自業務經營有關的行政、電信、電腦、付款或其他服務的任何代理人、承包商或第三方服務供應商；
- 香港聯交所、證監會及任何其他法定監管機構或政府部門或法例、規則或法規規定的其他機構；及
- 證券持有人與或擬與之進行交易的任何人士或機構，例如其銀行、律師、會計師或股票經紀等。

4. 保留個人資料

本公司及其香港證券登記處將按收集個人資料所需的用途保留證券申請人及持有人的個人資料。無需保留的個人資料將會根據條例銷毀或處理。

5. 查閱及更正個人資料

證券持有人有權確定本公司或香港證券登記處是否持有其個人資料，並有權索取有關該資料的副本及更正任何不準確資料。本公司及香港證券登記處有權就處理有關要求收取合理費用。

所有查閱資料或更正資料的要求應按招股章程「公司資料」一節所披露或不時通知的本公司註冊地址送交公司秘書，或向本公司的香港證券登記處的私隱事務主任提出。

閣下簽署申請表格或向香港結算發出電子認購指示，即表示同意上述各項。

樣版

This page is intentionally left blank
此乃白頁 特意留空

Sample

樣版

This page is intentionally left blank
此乃白頁 特意留空

Sample